{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:58:16Z","timestamp":1791917896870,"version":"4.3.4"},"reference-count":48,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health research"},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,11,22]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We have previously reported that the upregulation of galectin-9 (Gal-9) on CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T cells in HIV patients was associated with impaired T cell effector functions. Gal-9 is a ligand for T cell immunoglobulin and mucin domain-3, and its expression on T cells in cancer has not been investigated. Therefore, we aimed to investigate the expression level and effects of Gal-9 on T cell functions in patients with virus-associated solid tumors (VASTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>40 patients with VASTs through a non-randomized and biomarker-driven phase II LATENT trial were investigated. Peripheral blood mononuclear cells and tumor biopsies were obtained and subjected to immunophenotyping. In this trial, the effects of oral valproate and avelumab (anti-PD-L1) was investigated in regards to the expression of Gal-9 on T cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We report the upregulation of Gal-9 expression by peripheral and tumor-infiltrating CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T lymphocytes in patients with VASTs. Our results indicate that Gal-9 expression is associated with dysfunctional T cell effector functions in the periphery and tumor microenvironment (TME). Coexpression of Gal-9 with PD-1 or T cell immunoglobulin and ITIM domain (TIGIT) exhibited a synergistic inhibitory effect and enhanced an exhausted T cell phenotype. Besides, responding patients to treatment had lower Gal-9 mRNA expression in the TME. Translocation of Gal-9 from the cytosol to the cell membrane of T cells following stimulation suggests persistent T cell receptor (TCR) stimulation as a potential contributing factor in Gal-9 upregulation in patients with VASTs. Moreover, partial colocalization of Gal-9 with CD3 on T cells likely impacts the initiation of signal transduction via TCR as shown by the upregulation of ZAP70 in Gal-9+ T cells. Also, we found an expansion of Gal-9+ but\u2009not TIGIT+ NK cells in patients with VASTs; however, dichotomous to TIGIT+ NK cells, Gal-9+ NK cells exhibited impaired cytotoxic molecules but higher Interferon gamma (IFN-\u03b3) expression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data indicate that higher Gal-9-expressing CD8<jats:sup>+<\/jats:sup> T cells were associated with poor prognosis following immunotherapy with anti-Programmed death-ligand 1 (PD-L1) (avelumab) in our patients\u2019 cohort. Therefore, for the very first time to our knowledge, we report Gal-9 as a novel marker of T cell exhaustion and the potential target of immunotherapy in patients with VASTs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-001849","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T09:50:11Z","timestamp":1607766611000},"page":"e001849","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":79,"title":["Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors"],"prefix":"10.1136","volume":"8","author":[{"given":"Isobel","family":"Okoye","sequence":"first","affiliation":[{"name":"School of Dentistry, Faculty of Medicine and Dentistrty, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Dentistry, Faculty of Medicine and Dentistrty, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Motamedi","sequence":"additional","affiliation":[{"name":"Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Parashar","sequence":"additional","affiliation":[{"name":"School of Dentistry, Faculty of Medicine and Dentistrty, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-6145","authenticated-orcid":false,"given":"John W","family":"Walker","sequence":"additional","affiliation":[{"name":"Medical Oncology, Cross Cancer Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-2009","authenticated-orcid":false,"given":"Shokrollah","family":"Elahi","sequence":"additional","affiliation":[{"name":"School of Dentistry, Faculty of Medicine and Dentistrty, University of Alberta, Edmonton, AB, Canada"},{"name":"Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada"},{"name":"Medical Oncology, Cross Cancer Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada"},{"name":"Li Ka Shing Institute of Virology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"2025100301521312000_8.2.e001849.1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01215"},{"key":"2025100301521312000_8.2.e001849.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2006649"},{"key":"2025100301521312000_8.2.e001849.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2013.10.001"},{"key":"2025100301521312000_8.2.e001849.4","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000000917"},{"key":"2025100301521312000_8.2.e001849.5","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.153"},{"key":"2025100301521312000_8.2.e001849.6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines targeting helper T cells for cancer immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"2025100301521312000_8.2.e001849.7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00018-017-2686-7","article-title":"CD4 and CD8 T lymphocyte interplay in controlling tumor growth","volume":"75","author":"Ostroumov","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"2025100301521312000_8.2.e001849.8","doi-asserted-by":"publisher","DOI":"10.1038\/nature01441"},{"key":"2025100301521312000_8.2.e001849.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0"},{"key":"2025100301521312000_8.2.e001849.10","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/925135"},{"key":"2025100301521312000_8.2.e001849.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.01.005"},{"key":"2025100301521312000_8.2.e001849.12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00760"},{"key":"2025100301521312000_8.2.e001849.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0132-0"},{"key":"2025100301521312000_8.2.e001849.14","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1832"},{"key":"2025100301521312000_8.2.e001849.15","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4314"},{"key":"2025100301521312000_8.2.e001849.16","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2422"},{"key":"2025100301521312000_8.2.e001849.17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-389585"},{"key":"2025100301521312000_8.2.e001849.18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017954108"},{"key":"2025100301521312000_8.2.e001849.19","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwq214"},{"key":"2025100301521312000_8.2.e001849.20","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.biocel.2012.05.003","article-title":"Association of HLA-alleles with the immune regulation of chronic viral infections","volume":"44","author":"Elahi","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"2025100301521312000_8.2.e001849.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.011"},{"key":"2025100301521312000_8.2.e001849.22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132687"},{"key":"2025100301521312000_8.2.e001849.23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901114"},{"key":"2025100301521312000_8.2.e001849.24","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1900087"},{"key":"2025100301521312000_8.2.e001849.25","doi-asserted-by":"crossref","first-page":"ji1901481","DOI":"10.4049\/jimmunol.1901481","article-title":"Galectin-9 and vista expression define terminally exhausted T cells in HIV-1 infection","volume":"204","author":"Shahbaz","year":"2020","journal-title":"J Immunol"},{"key":"2025100301521312000_8.2.e001849.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2013.04.006"},{"key":"2025100301521312000_8.2.e001849.27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122745","article-title":"Galectins and carcinogenesis: their role in head and neck carcinomas and thyroid carcinomas","volume":"18","author":"Kindt","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025100301521312000_8.2.e001849.28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.7.3631"},{"key":"2025100301521312000_8.2.e001849.29","doi-asserted-by":"crossref","unstructured":"Ohue Y , Koji K , Oka M , et al . Discriminant function for predicting survival of lung adenocarcinoma patients developed by using immune parameters of PD-L1, Gal-9, and XAGE1 expression on tumor cells and T cell infiltration score. Cancer immunology research 2016;4.","DOI":"10.1158\/2326-6074.CRICIMTEATIAACR15-A008"},{"key":"2025100301521312000_8.2.e001849.30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2606"},{"key":"2025100301521312000_8.2.e001849.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008696","article-title":"Selective upregulation of CTLA-4 on CD8+ T cells restricted by HLA-B*35Px renders them to an exhausted phenotype in HIV-1 infection","volume":"16","author":"Elahi","year":"2020","journal-title":"PLoS Pathog"},{"key":"2025100301521312000_8.2.e001849.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700742"},{"key":"2025100301521312000_8.2.e001849.33","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ecco-jcc\/jjy147","article-title":"Lower abundance and impaired function of CD71+ erythroid cells in inflammatory bowel disease patients during pregnancy","volume":"13","author":"Dunsmore","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025100301521312000_8.2.e001849.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2025100301521312000_8.2.e001849.35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"2025100301521312000_8.2.e001849.36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425"},{"key":"2025100301521312000_8.2.e001849.37","doi-asserted-by":"crossref","first-page":"98215","DOI":"10.18632\/oncotarget.21003","article-title":"Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling","volume":"8","author":"Okoye","year":"2017","journal-title":"Oncotarget"},{"key":"2025100301521312000_8.2.e001849.38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hep.28847","article-title":"CD14+ monocyte-derived galectin-9 induces natural killer cell cytotoxicity in chronic hepatitis C","volume":"65","author":"Nishio","year":"2017","journal-title":"Hepatology"},{"key":"2025100301521312000_8.2.e001849.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.06.019"},{"key":"2025100301521312000_8.2.e001849.40","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-005-5050-6"},{"key":"2025100301521312000_8.2.e001849.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.010"},{"key":"2025100301521312000_8.2.e001849.42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8941260","article-title":"Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response","volume":"2016","author":"Reiser","year":"2016","journal-title":"J Immunol Res"},{"key":"2025100301521312000_8.2.e001849.43","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2006.00391.x"},{"key":"2025100301521312000_8.2.e001849.44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.oraloncology.2017.02.005","article-title":"Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck","volume":"67","author":"Hanna","year":"2017","journal-title":"Oral Oncol"},{"key":"2025100301521312000_8.2.e001849.45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2481"},{"key":"2025100301521312000_8.2.e001849.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903474106"},{"key":"2025100301521312000_8.2.e001849.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2025100301521312000_8.2.e001849.48","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.189"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:52:21Z","timestamp":1759481541000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,12]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jitc-2020-001849"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001849","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}